Trophos SA announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA). The independent Data Monitoring Committee (DMC) has reviewed the treatment effect at one year on the primary outcome measure o more
To use all functions of this page, please activate cookies in your browser.
